MX2011008131A - Lineas celulares que expresan cftr y los métodos para utilizarlas. - Google Patents

Lineas celulares que expresan cftr y los métodos para utilizarlas.

Info

Publication number
MX2011008131A
MX2011008131A MX2011008131A MX2011008131A MX2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A
Authority
MX
Mexico
Prior art keywords
cftr
cell
cells
intron
suppression
Prior art date
Application number
MX2011008131A
Other languages
English (en)
Spanish (es)
Inventor
Kambiz Shekdar
Dennis J Sawchuk
Jessica Langer
Srinivasan P Venkatachalan
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of MX2011008131A publication Critical patent/MX2011008131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049—Channel-conductance-controlling ATPase (3.6.3.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011008131A 2009-02-02 2010-02-01 Lineas celulares que expresan cftr y los métodos para utilizarlas. MX2011008131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14931209P 2009-02-02 2009-02-02
PCT/US2010/022778 WO2010088630A2 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Publications (1)

Publication Number Publication Date
MX2011008131A true MX2011008131A (es) 2012-01-20

Family

ID=42396394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008131A MX2011008131A (es) 2009-02-02 2010-02-01 Lineas celulares que expresan cftr y los métodos para utilizarlas.

Country Status (6)

Country Link
US (2) US20120058918A1 (enExample)
EP (1) EP2393930A4 (enExample)
JP (1) JP2012516686A (enExample)
CA (1) CA2751215A1 (enExample)
MX (1) MX2011008131A (enExample)
WO (1) WO2010088630A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297674A1 (en) * 2008-01-22 2010-11-25 Chromocell Corporation NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM
NZ601353A (en) * 2008-02-01 2014-06-27 Chromocell Corp Cell lines and methods for making and using them
US8945848B2 (en) 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
US20120302573A1 (en) * 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
US20130014288A1 (en) * 2011-06-06 2013-01-10 Carnegie Mellon University Novel reporter-tagged recombinant membrane proteins with transmembrane linkers
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
AU2017264612A1 (en) * 2016-05-09 2018-11-22 Proteostasis Therapeutics, Inc. Methods of identifying CFTR modulators
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN111910008B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种鸡生长发育相关的分子标记及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) * 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing
WO2004020596A2 (en) * 2002-08-30 2004-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Polypeptides for increasing mutant cftr channel activity
WO2005120497A2 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CA2600869A1 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
KR101599062B1 (ko) * 2005-04-13 2016-03-02 아스트라제네카 아베 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포
JP2009537179A (ja) * 2006-05-19 2009-10-29 ザ スクリップス リサーチ インスティテュート 蛋白質ミスフォールディングの処置
US7989675B2 (en) * 2007-03-28 2011-08-02 University Of Iowa Research Foundation Method of identifying compounds using a transgenic pig model of cystic fibrosis

Also Published As

Publication number Publication date
CA2751215A1 (en) 2010-08-05
JP2012516686A (ja) 2012-07-26
EP2393930A2 (en) 2011-12-14
US20150315554A1 (en) 2015-11-05
WO2010088630A2 (en) 2010-08-05
US20120058918A1 (en) 2012-03-08
EP2393930A4 (en) 2012-08-15
WO2010088630A3 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US20150315554A1 (en) Cell lines expressing cftr and methods of using them
Boeckers et al. C‐terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3
Chillarón et al. Heteromeric amino acid transporters: biochemistry, genetics, and physiology
Quamme Molecular identification of ancient and modern mammalian magnesium transporters
Carneiro et al. The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter
Ma et al. Diverse trafficking patterns due to multiple traffic motifs in G protein-activated inwardly rectifying potassium channels from brain and heart
ES2640817T3 (es) Líneas celulares que expresan Nav y métodos para su utilización
Borjigin et al. A novel pineal night-specific ATPase encoded by the Wilson disease gene
Piters et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function
Kannangara et al. BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters
CN103525751B (zh) 细胞系以及制备和使用其的方法
US20080085323A1 (en) Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
Huang et al. Visual Arrestin 1 acts as a modulator for N-ethylmaleimide-sensitive factor in the photoreceptor synapse
Boileau et al. The short splice variant of the γ2 subunit acts as an external modulator of GABAA receptor function
Schönauer et al. Novel nephronophthisis-associated variants reveal functional importance of MAPKBP1 dimerization for centriolar recruitment
Larasati et al. Novel mutation at Cys225 in GNAO1‐associated developmental and epileptic encephalopathies: clinical, molecular, and pharmacological profiling of case studies
Benhadda et al. Serotonin 2B receptor by interacting with NMDA receptor and CIPP protein complex may control structural plasticity at glutamatergic synapses
Li et al. Sialin2 functions as a mammalian nitrate sensor to sustain mitochondrial homeostasis
KR20070092767A (ko) 시노비올린 활성 조절 작용의 검출 방법
EP3940384A1 (en) Method for screening compound for treating or preventing polyq-related neurodegenerative diseases
Merillon et al. Biallelic WDR91 variants cause a neurodevelopmental disorder through impaired endosomal maturation and autophagy dysregulation
Dubreuil Molecular and genetic dissection of the membrane skeleton in Drosophila
Gu et al. The middle lipin (M-Lip) domain is a new dimeric protein fold that binds membranes
Dahimene et al. The interplay between splicing of exons 18a and 47 differentially affects membrane targeting and function of human CaV2. 2
Deb et al. DE NOVO VARIANTS IN THE POLY (RC)-BINDING PROTEIN GENE PCBP1 CAUSE A NEURODEVELOPMENTAL DISORDER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal